Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States.
Diabetes Ther
January 2025
Eli Lilly and Company, Indianapolis, IN, USA.
Introduction: The study objective was to describe characteristics and utilization patterns of tirzepatide users with type 2 diabetes (T2D) using the Healthcare Integrated Research Database in the USA.
Methods: Adults (≥18 years) included had T2D diagnosis; ≥1 tirzepatide claim (May 2022-January 2023; first claim date = index date); and continuous medical and pharmacy enrollment during the 6-month baseline and follow-up periods from the index date. Baseline demographics, clinical characteristics, and 6-month follow-up dosing and treatment patterns were summarized descriptively.
Treatment of e-cigarette use among hospitalised adolescents and young adults: a protocol for intervention development and evaluation of preliminary efficacy and implementation outcomes in a randomised controlled trial.
BMJ Open
January 2025
Hospital Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA
Introduction: Hospitalisation represents an opportunity to identify and treat e-cigarette use among adolescents and young adults (AYAs). Knowledge on how to provide this care is lacking. We aim to fill this gap by developing an e-cigarette use intervention and evaluating preliminary efficacy and implementation outcomes among hospitalised AYAs.
View Article and Find Full Text PDFIntercostal Nerve Cryoablation During Lobectomy for Postsurgical Pain: A Safe and Cost-Effective Intervention.
Pain Ther
February 2025
Medical College Georgia, 1120 15th Street, BA 4300, Augusta, GA, USA.
Introduction: The cost benefit of intercostal nerve cryoablation during surgical lobectomy for postoperative pain management is unknown. The current study compared hospital economics, resource use, and clinical outcomes during the index stay and accompanying short-term follow-up. Patients who underwent lobectomy with standard of care treatment for postsurgical pain management and cryoablation were compared to those with standard of care treatment only.
View Article and Find Full Text PDFComparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.
Adv Ther
December 2024
Salt Lake City Veterans Affairs Health, Salt Lake City, UT, USA.
Article Synopsis
- - Psoriatic arthritis (PsA) is a long-term inflammatory disease that requires ongoing treatment, with options like guselkumab and IL-17A inhibitors (ixekizumab, secukinumab) approved for use in adults by the FDA.
- - A retrospective analysis studied adults with PsA who started treatment with either guselkumab or IL-17A inhibitors, assessing how long they continued their therapy based on insurance claims data from July 2020 to June 2022.
- - Results showed that patients on guselkumab were significantly more likely to stick with their treatment for at least a year compared to those on IL-17A inhibitors, with longer median persistence and lower discontinuation rates for the gus
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!